Mikhail Blagosklonny and His Investigation Of Hyperfunction and the Miraculous Rapamycin

Aging doesn’t have to be something that people will radically shun and fear. It doesn’t have to be something that people can just ignore. It no longer has to be a taboo subject that people will feel awkward talking about today. Aging is a topic that people don’t want to talk about in public, but it is a worthy topic to discuss. In fact, it is worth researching, too. Today, Mikhail V. Blagosklonny is the man investigating more about aging and has found new innovative technology that helps people cope with this condition and more information click here.


The Life-Extending Rapamycin

Rapamycin is an element in Mikhail’s research, and he deals with the studies of it to find out more efficient ways to use it for people’s benefits. The recent discoveries in Rapamycin have contributed a lot to an improvement of how people deal with aging and other related conditions that may prove problematic for those beauty conscious patients.

In the research of Mikhail, an analysis showed that aging is neither driven by the damage of the molecules in the body nor is it just caused by random damage of any type or sort. Mikhail showed in his analysis that there’s more to it than just damaged molecules. In his research, he showed that the injury to the skin that causes aging has nothing to do with random molecular deterioration. His theory is, in fact, saying that the aging process may be related to hyperfunction and Mikhail’s lacrosse camp.

Dr. Mikhail inferred that hyperfunction is the main characteristic that suggests the aging process. In his research, he mentioned that to help augment and change the way the hyperfunction works, Rapamycin should incorporate in the aging process. To make sure that there is enough Rapamycin for the body to help alter the hyperfunction system, Mikhail suggests adding ways to make sure that the body has enough of it.

Mikhail argues that the molecular damage theory shouldn’t form the first understanding of how aging works and how this aging process accumulates over time. This argument is not the theory that Mikhail believes, and so this process doesn’t necessarily limit the span of life that a person experiences. Hyperfunction theory replaces the arguments in the damaged molecules theory and well suggests that with the help of Rapamycin, the aging process won’t find itself causing the problem to a person’s aging issues and Mikhail’s lacrosse camp.


About Mikhail Blagosklonny

Dr. Mikhail is the Professor of Oncology at the Roswell Park Cancer Institute. He is now the scientist who concentrates a lot of his time in studying cancer and aging. His concentration on the issues, parameters, and benefits of using Rapamycin makes him one of the leading doctors who study how diseases relate to hyperfunction and not just to molecular damages related to aging. The field of expertise of Mikhail includes a lot of focus on anti-aging medicine and oncology.

Mikhail went to First Pavlov State Medical University of St. Petersburg and since then established himself a scholar. Mikhail is also known for the arguments he made on how the role of TOR signaling and rapamycin are related to extending one’s life.

More visit:

Jennifer Walden, Best Female Plastic Surgeon in Texas

Dr. Jennifer Lee Walden is a leading plastic surgeon in Austin, Texas, and her main area of specialization is breast lift augmentation and facial surgery. Also, she has reviewed and presented in both areas locally and internationally. Dr. Walden is listed among the few women elected to serve on various boards, and she is a certified Board member of the American Society for Aesthetic Plastic Surgery.


About Jennifer Walden

Jennifer Walden charges about 7000 dollars for breast augmentation and 9000 dollars for facelifts as well as nose jobs. Jennifer makes use of the latest technological advancements to perform her procedures. For example, she uses ThermiVa, a radio-frequency technology system controlled based on temperature for vaginal tightening and rejuvenation procedures. Walden also uses a 3-D imaging technique known as Vectra that reviews and visualizes patients’ looks before they undergo surgery.

Walden also serves as an aesthetic consultant for several companies such as ThermiAestheticcs, Sciton Inc, and Venus Concept. As a result, In 2014, Dr. Walden was named among the 24 Best Beauty Surgeons by Harper Bazaar. Apart from performing plastic surgery procedures, Jennifer is a media commentator and has been featured on ABC news, E! and Dr 90210, just to name a few. Walden is also an academic writer, and she has co-authored the popular cosmetic book, the Aesthetic Plastic Surgery, a popular cosmetic book and learn more about Dr. Walden.

Jennifer Walden obtained a Bachelor’s degree in Biology from the University of Texas. After her degree, she undertook her medical residency at the University of Texas Medical Branch and had the opportunity to graduate as a salutatorian of her year. After her residency, Dr. Jennifer began her career at the Manhattan Eye, Throat and Ear Hospital under the mentorship of the well-known Dr. Sherrell Aston and more information click here.

Jennifer’s primary goal is to help her clients enhance the looks and offer the best quality safety measures and patient care services.

More Visit:

Amicus Therapeutics Fight Against Orphan Diseases

Located in Cranbury, New Jersey, United States of America, Amicus Therapeutics is a public biopharmaceutical firm founded in February 4, 2002. During its formation, different venture firms came together to form it. Radius Ventures, Canaan Partners and New Enterprise Associates are examples of these firms.


From 2004 to 2008, Amicus operated on a single site in New Jersey. It was in late 2008, that it expanded to San Diego. In 2009 Amicus Therapeutics went public and acquired the trading symbol FOLD. Later on the same year, Amicus ended a contract between them and Shire. This was mainly attributed that they faced financial setbacks. It was in 2010 that it acquired grants from various foundations. The Michael J. Fox Foundation was among the firm’s donators. These donations made Amicus Therapeutics get back to its feet and even acquired few other firms. For example, Callidus Biopharma acquired in 2013 and Scioderm which was acquired 2 years later.


There are three top people that are involved in running and conducting the affairs of Amicus Therapeutics. They include John Crowley, who is the Chief Executive Officer, William Baird, who is the Chief Financial Officer and Bradley Campbell. Bradley Campbell serves as the Chief Operations Officer. All of the three individuals are people of great skill and expertise in the pharmaceutical industry.


John Crowley, for example, is a man of great experience in the field of business and Medicine. Harvard Business School was one of the Universities he attended, where he graduated with an MBA degree in 1997. He took part in the foundation of Novazyme Pharmaceuticals and Orexigen Therapeutics before joining Amicus Therapeutics (GoogleFinance). The research conducted at Amicus Therapeutics is mainly based on rare and orphan diseases. The Amicus team is heavily driven by the desire to develop enzyme replacement therapies.


Ever since February 2014, Amicus Therapeutics has been doing research on the Fabry disease ( Recently the firm developed Galafold also known as Migasalat. This is a treatment for Fabry disease and is aimed at control endogenous mutant alpha-galactosidase. Fabry disease is characterized by patients having strokes, pain throughout the body, heart disease or even kidney failure. If not controlled, the disease may lead to death. Amicus Therapeutics also has the ambition of coming up with the cure of the Pompe Disease and the Epidermolysis Bullosa. Truly every single day the team at Amicus Therapeutics works tirelessly to help and give the best available care to their patients.